ONC
HealthcareBeOne Medicines Ltd. · Medical - Pharmaceuticals · $33B
What is BeOne Medicines Ltd.?
BeOne Medicines is a global oncology company focused on discovering and commercializing innovative cancer therapies. Formerly known as BeiGene, the company rebranded in late 2024 and redomiciled to Basel, Switzerland in 2025, while maintaining a major presence in Cambridge, Massachusetts.
BeOne Medicines generates revenue by developing and selling targeted cancer therapies and immuno-oncology treatments. Its commercial portfolio includes approved drugs for blood cancers and solid tumors sold in the U.S., Europe, China, and other major markets. The company combines internal research with external partnerships to advance a broad pipeline spanning hematologic malignancies and solid tumors, positioning itself as a fully integrated global oncology business.
Founded in 2010, BeOne Medicines operates across more than 45 countries on six continents.
- Brukinsa (zanubrutinib) — BTK inhibitor for blood cancers
- Tevimbra (tislelizumab) — PD-1 antibody for multiple cancer types
- Immuno-oncology pipeline across hematologic and solid tumor indications
- Global commercial infrastructure spanning six continents
- External partnership-sourced assets complementing internal R&D
Is ONC a Good Stock to Buy?
UQS Score rates ONC as Good overall, reflecting a mixed but forward-leaning profile for a large-cap oncology company.
BeOne's standout pillars are Growth and Risk — the company is expanding its commercial footprint at a pace that ranks among the stronger performers in the healthcare sector, while its risk profile suggests a relatively manageable balance sheet and operational structure for a company at this stage. The Moat pillar lands at Neutral, reflecting meaningful but still-developing competitive differentiation.
The Quality pillar registers as Weak, pointing to profitability metrics that trail sector peers — a common trait for high-investment oncology companies. Valuation is Elevated, meaning the market has already priced in considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ONC pay dividends?
No — BeOne Medicines Ltd. does not currently pay a dividend.
ONC does not currently pay a dividend. BeOne Medicines is in an active investment phase, directing capital toward clinical development, global commercialization, and pipeline expansion. For growth-stage oncology companies, reinvesting cash into R&D and market penetration is the typical capital allocation priority rather than returning cash to shareholders.
When does ONC report earnings?
BeOne Medicines reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue growth has been driven primarily by accelerating Brukinsa sales across major markets, with the company continuing to scale its global commercial operations. Profitability remains a work in progress as the company balances heavy R&D investment against expanding top-line momentum.
For the most recent quarter's results and guidance, visit BeOne Medicines' official investor relations page.
ONC Price History
-12.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BeOne Medicines Ltd.?
Based on BeOne Medicines Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ONC Long-term Outlook
BeOne's Strong Growth pillar suggests the company's commercial trajectory remains on an upward path, supported by expanding approvals and deepening market penetration for its lead assets. The Strong Risk pillar adds confidence that near-term financial stability is not a primary concern. However, the Elevated Valuation pillar signals that much of this growth expectation is already reflected in the current share price, leaving limited margin for execution shortfalls. Quality remaining Weak means sustained profitability improvement will be a key milestone investors watch.
Growth drivers
- Continued global uptake of Brukinsa across approved blood cancer indications
- Expanding Tevimbra approvals in solid tumor markets outside China
- Pipeline progression across hematologic malignancies and combination therapies
Key risks
- Elevated valuation leaves little room for clinical or commercial disappointments
- Path to sustained profitability remains uncertain given heavy R&D spend
- Competitive pressure from established oncology players in key therapeutic areas
ONC vs Peers
BeOne Medicines operates in a competitive oncology landscape alongside a range of companies at different stages of development.
Galecto focuses on galectin inhibition for fibrosis and oncology, representing a narrower pipeline focus compared to BeOne's broad commercial and clinical portfolio.
Cullinan Therapeutics pursues a modular oncology pipeline model, concentrating on early-stage assets without the global commercial infrastructure BeOne has built.
Atai Beckley operates primarily in neuropsychiatric therapeutics, making it a tangential peer by sector classification rather than a direct oncology competitor.
Frequently Asked Questions
What does BeOne Medicines do?
BeOne Medicines is a global oncology company that discovers, develops, and sells cancer therapies. Its commercial portfolio includes Brukinsa for blood cancers and Tevimbra for multiple cancer types. The company operates in over 45 countries and combines internal R&D with external partnerships to build a broad oncology pipeline.
Does ONC pay dividends?
ONC does not pay a dividend. BeOne Medicines is in an active growth and investment phase, prioritizing capital allocation toward clinical development and global commercialization rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does ONC report earnings?
BeOne Medicines reports on a quarterly cadence, standard for US-listed companies. Specific dates are not covered by our data source — check the company's investor relations page for the current earnings calendar and upcoming reporting schedule.
Is ONC a good stock to buy?
UQS Score rates ONC as Good overall. The Growth and Risk pillars are Strong, but the Quality pillar is Weak and Valuation is Elevated. Whether ONC fits your portfolio depends on your tolerance for pre-profitability growth companies trading at a premium. The full pillar breakdown is available to Pro members.
Is ONC overvalued?
The UQS Valuation pillar for ONC is rated Elevated, indicating the current market price reflects significant growth expectations already. This does not mean the stock will decline, but it does suggest investors are paying a premium relative to current fundamentals. View the complete valuation analysis with a Pro account.
How does ONC compare to its competitors?
Among the peers listed — Galecto, Cullinan Therapeutics, and Atai Beckley — BeOne Medicines stands out for its established commercial products and global operational scale. Most listed peers are earlier-stage or operate in adjacent therapeutic areas, making direct comparison limited. The UQS platform provides side-by-side scoring for a structured view.
What is ONC's market cap bracket?
ONC is classified as a large-cap stock, reflecting BeOne Medicines' significant scale as a global oncology company with a commercial presence across more than 45 countries. Large-cap status generally implies greater liquidity and institutional coverage relative to smaller biotech peers.
Who founded BeOne Medicines?
BeOne Medicines was founded in 2010. Founding details, including the names of co-founders, are widely available through public sources and the company's official investor relations materials. The company rebranded from BeiGene to BeOne Medicines in late 2024.
Is ONC a long-term quality investment?
As a long-term quality indicator, ONC presents a mixed picture. The Strong Growth pillar points to durable commercial momentum, while the Weak Quality pillar reflects profitability that has not yet matured. Long-term investors should weigh the company's pipeline depth and global reach against its current earnings profile. Pro members can access the full analysis.
What is the main competitive advantage of BeOne Medicines?
BeOne's competitive positioning rests on its dual commercial assets — Brukinsa and Tevimbra — combined with a global infrastructure spanning six continents. Its ability to operate across both Western and Asian markets, particularly China, gives it a geographic reach that many oncology peers lack. The Moat pillar is currently rated Neutral, suggesting this advantage is real but still developing.
What sector does ONC belong to?
ONC operates in the Healthcare sector, specifically within oncology — one of the most active and competitive areas of biopharmaceutical development. Oncology companies are often evaluated on pipeline depth, approval track record, and the path to commercial profitability, all of which factor into the UQS scoring framework.
Unlock Full ONC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for ONC
- ✓Access complete financial metrics and trend data
- ✓Compare ONC against sector peers side by side
- ✓See Growth and Risk pillar detail behind the rating
- ✓Get the full analyst-style breakdown in one place
Pro Analysis
ONC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 55.1 | 38.7 | 42.0 | 80.0 | 97.8 | 28.6 | -0.4 |
| May 3, 2026 | 55.5 | 38.7 | 42.0 | 80.0 | 97.8 | 30.8 | +0.2 |
| Apr 26, 2026 | 55.3 | 38.7 | 42.0 | 80.0 | 97.8 | 30.0 | +0.4 |
| Apr 19, 2026 | 54.9 | 38.7 | 42.0 | 80.0 | 97.8 | 27.3 | -0.4 |
| Apr 18, 2026 | 55.3 | 38.7 | 42.0 | 80.0 | 97.8 | 29.4 | -1.6 |
| Apr 14, 2026 | 56.9 | 38.7 | 42.0 | 80.0 | 97.8 | 40.1 | +0.1 |
| Apr 12, 2026 | 56.8 | 38.7 | 42.0 | 80.0 | 97.8 | 39.4 | +0.1 |
| Apr 9, 2026 | 56.7 | 38.7 | 42.0 | 80.0 | 97.8 | 39.2 | -0.1 |
| Apr 5, 2026 | 56.8 | 38.9 | 42.0 | 80.0 | 97.8 | 39.2 | +0.5 |
| Apr 4, 2026 | 56.3 | 38.8 | 42.0 | 80.0 | 97.8 | 36.3 | +0.3 |
ONC — Pillar Breakdown
Quality
— 50.1/100 (25%)BeOne Medicines Ltd. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)BeOne Medicines Ltd. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 95.4/100 (15%)BeOne Medicines Ltd. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 28.8/100 (15%)BeOne Medicines Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)BeOne Medicines Ltd. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ONC.
Score Composition
Financial Data
More Stock Analysis
How is the ONC UQS Score Calculated?
The UQS (Unified Quality Score) for BeOne Medicines Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BeOne Medicines Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BeOne Medicines Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.